Bellus Health, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit

- April 15th, 2021

Investors are encouraged to contact attorney Lesley F. Portnoy to determine eligibility to participate in this action, by phone 310-692-8883 or email or click here to join the case. Before the market opened on July 6, 2020, BELLUS announced topline results from its Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough. According to Bellus, the trial “did not achieve statistical significance …

Investors with losses are encouraged to contact the firm before May 17, 2021 ; click here to submit trade information

Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.

Before the market opened on July 6, 2020, BELLUS announced topline results from its Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough. According to Bellus, the trial “did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency at any dose tested.”

Bellus’ stock price fell $9.05, or 75%, on this news, over two consecutive trading sessions to close at $2.97 on July 8, 2020, thereby injuring investors.

It is alleged in this complaint that Bellus made materially misleading and/or false statements, as well as failed to disclose material adverse facts about Bellus’ business, operations, and prospects. Specifically, the complaint alleges that Bellus knew, and failed to disclose, that while BLU-5937’s “high selectivity” contributed to the drug causing little to no taste alteration in chronic cough patients, high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company’s Phase 2 trial.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Tags

Leave a Reply